Episode Summary



Developing non-traditional antibiotics promises novel strategies to combat multidrug-resistant organisms but would they work? Are they feasible to develop?

Topics discussed:

  • The notion of non-traditional antibiotics as potential therapeutics against MDR organisms
  • Increasing our understanding on the clinical efficacy of non-traditional antibiotics
  • Regulatory pathways for approval of such compounds

Guest:

  • Dr. John Rex, Chief Medical Officer, F2G Ltd. | Editor-in-Chief, AMR.solutions

Visit aac.asm.org to browse issues and/or submit a manuscript.

Subscribe to Editors in Conversation (free) on Apple Podcasts, Google Podcasts, Android, Spotify, Email.